CRNX

As of 2026-09-11, CRNX scores 34out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. CRNX trades at $84.95, within its fair-value band.

CRNX scores 34 out of 100 on QNTM's five-factor model — a low-conviction reading — at 34 the factor profile is among the weaker names in the universe. Its strongest factor is volume at 75 (strong), where trading volume confirms genuine accumulation, followed by sentiment at 46. The weakest is value at 0, where valuation looks stretched. Among Healthcare stocks it sits in the lower 17% of Healthcare names by composite.

On valuation, CRNX is priced near the floor of its own recent range — the cheap end on the model's valuation read. The profile is lopsided — a few factors carry it while others drag, so the composite masks real disagreement underneath. The blended composite before the macro overlay was 35. Same-sector names the model rates nearby include HALO, THC, HNGE.

This is a descriptive factor read on CRNX, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where CRNX sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-11.